BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT™, BriaCell’s lead candidate, in a Combination Study with immune checkpoint inhibitors such as the Incyte drugs INCMGA00012, an anti-PD-1 antibody similar to pembrolizumab (KEYTRUDA®; manufactured by Merck & Co., Inc., and epacadostat, an orally bioavailable small-molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1). The Combination Study is listed in ClinicalTrials.gov as NCT03328026.October 21, 2020: BriaCell Breast Cancer Survival Data: 13.3 Months Versus 7.2-9.8 Months January 13, 2020: BriaCell Provides Update on Remarkable Responder January 9, 2020: BriaCell Outlines New High Responding Patient Group ‘Biomarker’ Based on Cancer Grade
September 19, 2019: Remarkable Responder in Combination Study of Bria-IMT™ with KEYTRUDA® April 3, 2019: Bria-IMT™ with KEYTRUDA® (by Merck) combination study efficacy results; rapid additive or synergistic anti-tumor activity September 26, 2018: BriaCell announced Positive Proof of Concept Data in Phase I/IIa of Bria-IMT™ in Advanced Breast Cancer.
- BriaCell has achieved positive proof of concept based on data from a Phase I/IIa study of Bria-IMT™ in advanced breast cancer patients.
- The data shows promising anti-tumor activity of Bria-IMT™ in heavily pre-treated advanced breast cancer patients.
- Impressive Phase IIa efficacy data is similar to, or superior to, those of other approved breast cancer drugs when they were at a similar clinical-stage of development.
- The data shows an outstanding safety and tolerability profile for Bria-IMT™ in advanced breast cancer patients.
- The data confirms the “HLA Matching Hypothesis” (i.e. Patients who matched Bria-IMT™ at HLA level responded the most to the treatments) and supports BriaCell’s strategy for the development of Bria-OTS™, BriaCell’s first personalized off-the-shelf immunotherapy for advanced breast cancer.
About Bria-IMT™ (SV-BR-1-GM)
Developed and characterized by a team of dedicated scientists and clinicians, Bria-IMT™ (SV-BR-1-GM) is a targeted immunotherapy being developed for the treatment of breast cancer. Bria-IMT™ is a genetically engineered human breast cancer cell line with features of immune cells and clinically applied as a targeted immunotherapy.
Developed and characterized by a team of dedicated scientists and clinicians, Bria-IMT™ (SV-BR-1-GM) is a targeted immunotherapy for the treatment of breast cancer.
In short, Bria-IMT™ immunotherapy is a genetically engineered human breast cancer cell line which activates the immune cells to attack and destroy breast cancer tumors.
Mechanism of Action of Bria-IMT™: The mechanism of action of Bria-IMT™ is currently under investigation. It is likely that the expression of certain breast cancer antigens (proteins expressed in breast cancer cells) in Bria-IMT™ generates strong antibody and T-cell responses – which results in recognition and destruction of cancerous cells.
Bria-IMT™ is designed to secrete granulocyte/macrophage-colony stimulating factor (GM-CSF), a factor that stimulates components of the immune system. Specifically, GM-CSF activates T cells, a key component of the immune system, to recognize the tumor cells as foreign, and eliminate them. To amplify this action, we have combined Bria-IMT™ with other immune system activators including cyclophosphamide, and interferon-α, a cytokine. We believe this approach of simultaneous activation of the immune system via different pathways will improve the immune system response to attack and destroy cancer cells.
Using BriaCell’s novel technology platform and our strong R&D capabilities, we plan to develop immunotherapies for other cancer indications.